- Effect of Macitentan on Hospitalizations: Results From the SERAPH IN Trial2015 | 1. lékařská fakulta
- SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension2017 | 1. lékařská fakulta
- Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension2013 | 1. lékařská fakulta
- Long-Term Safety, Tolerability and Survival in Patients with Pulmonary Arterial Hypertension Treated with Macitentan: Results from the SERAPHIN Open-Label Extension2022 | 1. lékařská fakulta
- Macitentan in Pulmonary Arterial Hypertension: A Focus on Combination Therapy in the SERAPHIN Trial2018 | 1. lékařská fakulta
- Macitentan Improves Health- Related Quality of Life for Patients With Pulmonary Arterial Hypertension2017 | 1. lékařská fakulta
- Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis DUAL-1 and DUAL-2 Randomized Clinical Trials2016 | Publikace bez příslušnosti k fakultě
- Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN2015 | 1. lékařská fakulta
- Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases Insights From Pulmonary Arterial Hypertension2019 | 1. lékařská fakulta
- Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality2018 | 1. lékařská fakulta
- Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial2018 | 1. lékařská fakulta